Vertex Pharmaceuticals

Vertex Pharmaceuticals

Yahoo Finance • 5 days ago

NVIDIA And 2 Elite Undervalued Stocks To Own

Global public debt now sits near 100% of GDP, and the IMF is signaling a return to spending cuts and tighter money. That kind of backdrop often pushes investors toward companies that generate solid cash, carry sensible debt levels, and sti... Full story

Yahoo Finance • 10 days ago

Vertex (VRTX) or Regeneron (REGN)? Two Biotech Moats, Two Very Different Bets

Biotech companies are strange businesses to think about in terms of competitive advantages. A software company can lock customers into an ecosystem for years. A manufacturer can have a cost advantage. A biotech company, meanwhile, can spen... Full story

Yahoo Finance • 11 days ago

Vertex Pharmaceuticals And 2 Other Top Gene Therapy Stocks

Global bond yields recently hit multidecade highs, raising borrowing costs and putting pressure on many high growth sectors. When money gets more expensive, investors often look harder at balance sheets and valuations. That is where select... Full story

Yahoo Finance • 14 days ago

Could Vertex Pharmaceuticals (VRTX)’s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)?

On September 22, Truist analyst Danielle Brill identified a "significant positive readthrough" for Maze Therapeutics, Inc. (NASDAQ:MAZE) following positive Phase 2 topline data from Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). The da... Full story

Yahoo Finance • 18 days ago

Maze Therapeutics (MAZE) Shares Moved, So What Is Driving Attention Now?

Fresh Coverage Puts Maze Therapeutics in Focus Maze Therapeutics (MAZE) moved higher in pre-market trading on 23 September after CIBC began covering the clinical-stage kidney and metabolic disease specialist, with the share reaction unfol... Full story

Yahoo Finance • 19 days ago

Vertex Posts Positive Phase II Data on Kidney Disease Drug

Vertex Pharmaceuticals VRTX announced positive data from the phase IIb AMPLIFIED study, which evaluated its investigational drug, inaxaplin, for the treatment of patients with APOL1-mediated kidney disease ("AMKD") and modest proteinuria a... Full story

Yahoo Finance • 19 days ago

Autologous Hematopoietic Stem Cell Gene Therapy Market Global Report 2026: A $13.44 Billion Market by 2030 as Novartis, Vertex, CRISPR Therapeutics and Orchard Therapeutics Accelerate the Gene-Editing Race

Company Logo Boost ROI via rare-disease R&D, CRISPR therapies, scalable manufacturing, CDMO partnerships and regulatory incentives that accelerate approvals and commercialization. Autologous Hematopoietic Stem Cell Gene Therapy MarketAut... Full story

Yahoo Finance • 20 days ago

The Surprise That Sent Vertex — And Its Chief Rival — Soaring

Vertex stock popped Tuesday — while shares of rival Maze Therapeutics skyrocketed — on a surprise expansion for their kidney disease drugs. Continue Reading... Full story

Yahoo Finance • 20 days ago

Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this drugmaker have retur... Full story

Yahoo Finance • 22 days ago

3 Reasons CRISPR Therapeutics Stock Is Still a Buy After a Rocky 2026

It's been a disappointing couple of years for shareholders of biotechnology outfit CRISPR Therapeutics (NASDAQ: CRSP). This stock's barely up since the end of 2022, lagging the broad market's gains. It's not the performance that investors... Full story

Yahoo Finance • 24 days ago

Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $508.34, moving -1.55% from the previous trading session. The stock's performance was behind the S&P 500's daily gain of 0.17%. At the same time, the Dow lost 0.18%, and t... Full story

Yahoo Finance • 24 days ago

Is This Biotech Stock Too Cheap to Ignore After Its Latest Pullback?

Vertex Pharmaceuticals (NASDAQ: VRTX) has performed well in 2026. Its shares are up 13% year-to-date, while the S&P 500 is up 10%. However, after reaching $560.25 per share earlier this year, the company has dropped 8% from that 52-week hi... Full story

Yahoo Finance • 26 days ago

My Top 5 Favorite Stocks for an Uncertain Market

The S&P 500 has climbed this year, adding to three consecutive years of gains. But with levels near record highs, valuations relatively high, and concerns about artificial intelligence (AI) spending and rising inflation brewing, some inves... Full story

Yahoo Finance • 27 days ago

Vera Makes A Bullish Move — Times Three. Will It Hold Up To Competition?

Vera stock jumped Tuesday on positive test results for its kidney disease treatment, a rival to drugs from Otsuka and Vertex Pharmaceuticals. Continue Reading... Full story

Yahoo Finance • 28 days ago

Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

Choosing between Amgen (NASDAQ:AMGN) and Vertex Pharmaceuticals (NASDAQ:VRTX) requires balancing the stability of a diversified pharmaceutical giant against the high-growth, high-margin profile of a specialized biotechnology pioneer. Amge... Full story

Yahoo Finance • last month

Q2 Rundown: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs Other Therapeutics Stocks

Q2 Rundown: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs Other Therapeutics Stocks As the Q2 earnings season wraps, let's dig into this quarter's best and worst performers in the therapeutics industry, including Vertex Pharmaceuticals (NASDAQ:... Full story

Yahoo Finance • last month

3 Market-Beating Stocks for Long-Term Investors

3 Market-Beating Stocks for Long-Term Investors The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become... Full story

Yahoo Finance • last month

Where Will CRISPR Therapeutics Stock Be in 5 Years?

CRISPR Therapeutics (NASDAQ: CRSP) has already accomplished something most gene-editing companies are still trying to do: get a CRISPR-based medicine approved and onto the market. Now it has to prove it can build a business around the tech... Full story

Yahoo Finance • last month

IBB Just Beat the S&P 500 by 22 Points in Three Months. Are You Late to the Party?

Quick Read IBB surged 26% over three months versus SPY's 4%, as big pharma's price-insensitive buyouts of patent-cliff replacements rewarded IBB holders. XBI's equal-weight design returned 34% YTD versus IBB's 26%, making it the higher-to... Full story

Yahoo Finance • last month

Healthcare August recap: Moderna jumps 156% as biotech shines; DaVita sinks

[Health Care Medical Concept] ogichobanov/iStock via Getty Images The healthcare sector (XLV [https://seekingalpha.com/symbol/XLV]) gained 4.91% in August, outperforming the broader S&P 500 (SPY [https://seekingalpha.com/symbol/SPY]), whi... Full story